Health Care [ 3/12 ] | Biotechnology [ 10/73 ]
NASDAQ | Common Stock
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 3, 25 | 2.66 Increased by +192.31% | 1.09 Increased by +144.04% |
| Aug 4, 25 | 1.29 Increased by +143.40% | 1.22 Increased by +5.74% |
| May 5, 25 | 1.20 Increased by +3.89 K% | 1.03 Increased by +16.14% |
| Feb 24, 25 | 1.53 Increased by +410.00% | 1.85 Decreased by -17.39% |
| Nov 4, 24 | 0.91 Increased by +231.88% | 0.90 Increased by +1.11% |
| Aug 5, 24 | 0.53 Increased by +142.40% | 0.58 Decreased by -8.62% |
| May 6, 24 | 0.03 Increased by +101.70% | 0.15 Decreased by -80.00% |
| Feb 26, 24 | 0.30 Increased by +124.00% | -0.38 Increased by +178.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 97.80 M Increased by +16.65% | 79.36 M Increased by +192.00% | Increased by +81.15% Increased by +150.32% |
| Jun 30, 25 | 96.04 M Increased by +36.65% | 38.33 M Increased by +146.23% | Increased by +39.91% Increased by +80.19% |
| Mar 31, 25 | 88.18 M Increased by +94.88% | 35.73 M Increased by +3.73 K% | Increased by +40.52% Increased by +1.87 K% |
| Dec 31, 24 | 91.14 M Increased by +116.26% | 45.48 M Increased by +423.23% | Increased by +49.90% Increased by +141.94% |
| Sep 30, 24 | 83.84 M Increased by +879.91% | 27.18 M Decreased by -66.34% | Increased by +32.42% Decreased by -96.56% |
| Jun 30, 24 | 70.28 M Increased by +N/A% | 15.57 M Increased by +146.88% | Increased by +22.15% Decreased by N/A% |
| Mar 31, 24 | 45.25 M Increased by +N/A% | 932.00 K Increased by +102.06% | Increased by +2.06% Decreased by N/A% |
| Dec 31, 23 | 42.14 M Increased by +N/A% | 8.69 M Increased by +127.12% | Increased by +20.63% Decreased by N/A% |